News

Filter

Current filters:

Ganciclovir

1 to 9 of 106 results

UPDATE: ViroPharma discontinues Ph III maribavir trial, shares fall 5.3%

23-02-2009

Shares in USA-based ViroPharma fell 5.3% to $6.23 on February 13, after the firm cancelled a Phase III…

CytoveneGanciclovirNystatinOralVitrasert

Valcyte as effective as ganciclovir in CMV

14-05-2007

Swiss drug major Roche says that the results of a trial of its oral antiviral Valcyte (valganciclovir),…

CytoveneGanciclovirNystatinOralRocheValcyteValganciclovir HclVitrasert

Sirion gets US rights to Thea's Virgan

22-01-2007

Sirion Therapeutics, a Florida, USA-based ophthalmic-focused biopharmaceuticals company, has reached…

CytoveneGanciclovirVitrasert

Cerepro Ph III trial gets DSMB go ahead

15-01-2007

UK-based health care group Ark Therapeutics says that the observed side effect profile in a Phase III…

Amino AcidsCytoveneGanciclovirInjectionPhysostigmine SalicylateVitrasert

Positive new data for Roche's ganciclovir

31-05-2004

Results presented at the American Transplant Congress' annual meeting in Boston demonstrate that the…

AcyclovirCytoveneGanciclovirRocheValcyteValganciclovir HclVitrasertZovirax

Tokyo pharma stocks - week to July 21

28-07-2003

Tokyo saw an accelerated pace of pullback in the week to July 21 (four trading days because July 21 was...

CytoveneEisaiGanciclovirGlaxoSmithKlineGSKPrografProtopicRocheSankyoSchering AgtacrolimusVitrasert

Roche's Valcyte comparable to Cytovene

09-06-2003

Results from a 12-month pivotal Phase III study show that Roche's Valcyte (valganciclovir) is as effective…

CytoveneGanciclovirRocheValcyteValganciclovir HclVitrasert

1 to 9 of 106 results

COMPANY SPOTLIGHT

Menarini

Back to top